Last reviewed · How we verify
ALK HDM tablet
At a glance
| Generic name | ALK HDM tablet |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma (PHASE3)
- House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma (PHASE3)
- Efficacy and Safety Trial of the ALK HDM Tablet in House Dust Mite Allergic Subjects (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALK HDM tablet CI brief — competitive landscape report
- ALK HDM tablet updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI